Related Experiment Video
Updated: Jul 18, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated
Jesús Saavedra-Lozano1, José T Ramos, Francisco Sanz
1UT Southwestern Medical Center, Dallas, TX, USA. jsaavedra.hflr@salud.madrid.org
Insights
High-dose abacavir (ABC) combined with other antiretroviral (ARV) agents is safe and effective for treating HIV-associated encephalopathy (HIV-AE) in children, improving virologic, immunologic, and neuropsychological outcomes.
Area of Science:
- Pediatric Neurology
- Infectious Diseases
- Pharmacology
Background:
- HIV-associated encephalopathy (HIV-AE) is a severe neurological condition in children with Human Immunodeficiency Virus (HIV).
- The efficacy of antiretroviral (ARV) agents with good cerebrospinal fluid (CSF) penetration for HIV-AE is not well-defined.
- Abacavir (ABC) demonstrates good CSF penetration and has shown promise in adults with HIV dementia.
Purpose of the Study:
- To evaluate the safety and efficacy of an ARV regimen including high-dose abacavir (ABC) in children diagnosed with HIV-AE.
- To assess virologic, immunologic, and neuropsychological responses to the high-dose ABC regimen.
Main Methods:
- The study enrolled abacavir-naive children aged 3 months to 18 years with HIV-AE and virologic failure.
- Participants received a high-dose abacavir-containing ARV regimen.
- Safety, virologic load, CD4 counts, and neuropsychological function were assessed over 48 weeks.
Main Results:
- 14 out of 17 enrolled children completed 48 weeks of therapy with good overall tolerability.
- Significant reductions in HIV RNA levels were observed in both plasma and CSF.
- Mean increases in CD4 cell count and CD4% were noted, along with reduced soluble tumor necrosis factor receptor II concentrations.
- Children under 6 years old showed significant neuropsychological improvement.
Conclusions:
- Highly active antiretroviral therapy (HAART) including high-dose abacavir (ABC) is safe and effective in children with HIV-AE.
- The regimen demonstrated significant clinical, immunologic, and virologic benefits at 48 weeks.
- Younger children (under 6 years) experienced notable neuropsychological improvements, highlighting the regimen's impact on cognitive function.
Background:
HIV-associated encephalopathy (HIV-AE) is a severe neurologic condition that affects HIV-infected children. The potential benefit of antiretroviral (ARV) agents with good cerebrospinal fluid (CSF) penetration remains to be defined. Abacavir (ABC) achieves good CSF concentrations and studies of high-dose ABC showed benefit in adults with HIV dementia. The present study evaluated the safety and virologic, immunologic and neuropsychological responses of an ARV regimen including high-dose ABC in children with HIV-AE.
Methods:
Children between 3 months and 18 years old and abacavir-naive with HIV-AE and virologic failure were eligible.
Results:
: Seventeen children (16 ARV-experienced) were enrolled and 14 children completed 48 weeks of therapy. The overall tolerability was good; 2 children had a possible hypersensitivity reaction. At week 48, 53% and 59% of the children achieved HIV RNA levels below the limit of quantitation in plasma and CSF, respectively. The median (25%-75% range) change of HIV RNA from baseline to week 48 was -2.29 (-0.81 to -2.47) log10 copies/mL in plasma and -0.94 (0 to -1.13) log10 copies/mL in CSF. The mean increases in CD4 (+/-standard error of mean) cell count and CD4% were 427 (+/-169) cells/mm and 8% (+/-2), respectively. Concentrations of soluble tumor necrosis factor receptor II were reduced in plasma and CSF. Children less than 6 years of age demonstrated significant neuropsychological improvement at week 48.
Conclusions:
In the present study with a limited number of children, highly active ARV therapy including high-dose ABC showed a safety profile similar to standard dose ABC and provided clinical, immunologic and virologic response in children with HIV-AE at week 48. Children less than 6 years of age also demonstrated significant neuropsychological improvement.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Retroviruses
Inhibitors of Virion Maturation and Assembly
